Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

USP10-mediated PFKFB4 deubiquitination induces lung cancer radioresistance by activating the fumarate/Rad51 axis

ABSTRACT: Radioresistance is a major cause of radiotherapy failure in lung cancer, and its mechanism has not been fully elucidated. Glucose metabolism is closely related to radioresistance, and targeting key molecules in glucose metabolism is expected to increase radiosensitivity. Our study demonstrated that the expression of the gluconeogenic enzyme PFKFB4 was upregulated in lung cancer. Genetic silencing and pharmacological inhibition of PFKFB4 significantly enhanced lung cancer radiosensitivity. Mechanistically, the fumaric acid/Rad51 axis is crucial for PFKFB4-induced radioresistance. PFKFB4 inhibits histone demethylase KDM1A by upregulating fumaric acid, which in turn increases the level of H3K4me1 at the Rad51 promoter region and induces Rad51 transcriptional activation, and ultimately leads to lung cancer radioresistance. Furthermore, by constructing a library of ubiquitinated compounds, the deubiquitinating enzyme USP10 was identified as a key upstream molecule for stabilizing PFKFB4 expression, and USP10 silencing downregulated fumaric acid and Rad51 in a PFKFB4-dependent manner, which in turn increased lung cancer radiosensitivity. In conclusion, the present study reveals that USP10-mediated PFKFB4deubiquitination promotes lung cancer radioresistance through activation of the fumaric acid/Rad51 axis and provides important evidence for the clinical translation of PFKFB4.

ORGANISM(S): Homo sapiens

PROVIDER: GSE249850 | GEO | 2026/07/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Targeting FBXO22 enhances radiosensitivity of non-small cell lung cancer by inhibiting FOXM1/Rad51 axis

Project description:FBXO22 is the substrate recognition subunit of SCF E3 ubiquitin ligase, which plays an important role in the occurrence, development and therapeutic response of solid tumors.At present, the relationship between FBXO22 and radiosensitivity of lung cancer has not been fully elucidated.Here we present evidence to prove that abnormally expressed FBXO22 in lung cancer promotes transcriptional activation of homologous recombination enzyme Rad51 by up-regulating transcription factor FOXM1, which in turn induces radioresistance in lung cancer.By comparing with the reference data set of cMap database, Deguelin was identified as a small molecular inhibitor of FBXO22.Deguelin increases the radiosensitivity of lung cancer cells in vitro and in vivo in a FBXO22-dependent manner and is safely tolerated.This study revealed the identity of a novel radioresistance biomarker of FBXO22 and provided preclinical evidence for the clinical transformation of this target by screening small molecular inhibitors.

2024-02-07 | GSE235374 | GEO

Effects of PFKFB4 deletion on transcriptional reprogramming in breast cancer cells

Project description:To explore the mechanisms by which PFKFB4 promotes breast cancer metastasis, we CRISPR-Cas knock-out PFKFB4 in two breast cancer lines for RNA-seq to identify downstream target genes that are regulated by PFKFB4

2022-12-31 | GSE217132 | GEO

SPIN1 accelerates tumorigenesis and confers radioresistance of non-small cell lung cancer via orchestrating the FOXO3a/FOXM1 axis

Project description:Radioresistance is a predominant obstacle of effective treatments in non-small cell lung cancer (NSCLC), while the underlying mechanism remains incompletely elucidated. Spindlin 1(SPIN1) has been reported to participate in tumor initiation and progression, while its role in NSCLC tumorigenesis and radioresistance remains largely unknown. In this study, bioinformatics analysis, immunohistochemistry (IHC) and western blotting assays were performed to test SPIN1 expression in NSCLC samples and cell lines. The carcinogenic role of SPIN1 was evaluated by cell growth and proliferation, EdU staining, transwell and colony formation assays. Besides, the radiosensitivity of NSCLC cells was determined by clonogenic cell survival, neutral comet and γ-H2AX and Rad51 foci formation assays. Xenograft tumor model was constructed to access the effects of SPIN1 on tumorigenesis and radiosensitivity. Furthermore, RNA sequencing, quantitative real-time PCR, CHX and ubiquitination assays were applied to elucidate the correlation between SPIN1 and FOXO3a-FOXM1 axis. Therefore, our results suggest that the SPIN1-MDM2-FOXO3a/FOXM1 signaling axis is essential for NSCLC progression and radioresistance, and it could serve as therapeutic targets in irradiation-resistance NSCLC.

2024-11-20 | GSE276500 | GEO

Glycolysis enzyme PFKFB4 enhances HIF1a transcriptional activity by blocking the ubiquitin E3 ligase FBXO28 in glioblastoma

Project description:Glioblastoma is one of the most aggressive primary brain tumours in adults, with a dismal median overall survival of only 14 months after diagnosis1,2. Glioblastoma stem-like cells (GSCs), are particularly resistant to current therapies3,4, capable of self-renewal and tumour initiation5,6 and are hence thought to be major contributors to patient relapse. Glycolysis gene 6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase 4 (PFKFB4) is an essential gene for GSC survival, and is upregulated in these cells compared with in normal brain7. However, the mode of action of PFKFB4 in GSCs is unknown. Here we show a new role for PFKFB4 in the regulation of Hypoxia Inducible Factor 1 alpha (HIF1α) in GSCs. In a metabolic tracing study, we found that silencing PFKFB4 in GSCs resulted in a global downregulation of glucose metabolism. Gene expression profiling of PFKFB4-silenced GSCs revealed a downregulation of HIF1α target genes, and HIF1α protein levels are dramatically reduced in PFKFB4-silenced GSCs and other cancer cell lines. Finally, through mass spectrometric analysis of immunoprecipitated PFKFB4, we identified the ubiquitin E3 ligase, F box only protein 28 (FBXO28), as a new interaction partner of PFKFB4, which we show to regulate ubiquitylation and subsequent proteasomal degradation of HIF1α. Crucially, this newly discovered function of PFKFB4, coupled with its cancer specificity, provides a new strategy for inhibiting HIF1α in a cancer specific manner. Compounds which disrupt the interaction between PFKFB4 and FBXO28 could be interesting therapeutic agents against glioblastoma and other cancer entities in which PFKFB4 regulates HIF1α stability.

2022-10-13 | PXD009807 | Pride

Silencing of PFKFB4 in Glioblastoma Stem-like Cells

Project description:In order to investigate the crucial role of PFKFB4 in glioblastoma stem-like cell (GSC) survival, gene expression microarray-based transcriptome analysis was conducted on GSCs transduced for 4 days with PFKFB4 shRNA compared with GSCs transduced with shNT.

2019-01-05 | GSE108742 | GEO

Targeting Cyclin Y Inhibits STAT3 Activation to Enhance Radiosensitivity via Down-regulation of RRM2 in Lung Cancer

Project description:Purpose: Radioresistance is a main reason for the recurrence and metastasis of lung cancer. Cyclin Y is involved in normal physiological processes such as cell proliferation, growth and metabolism, as well as in the development of certain cancers. However, the function and mechanism of Cyclin Y in lung cancer are still unclear.Methods: Lung cancer cell lines were subjected to Cyclin Y knockdown using small interfering RNA (siRNA), and their growth and proliferation were assessed in vitro. Comet assay, γH2AX/Rad51 foci formation assay and clonogenic cell survival assay were performed to assess DNA damage and the DNA repair capacity. SgRNA transfection was applied to construct cell lines with stable Cyclin Y knockdown. Xenograft mouse models were used to validate the findings in vivo. RNA sequencing (RNA-seq) analysis was conducted to clarify the downstream target genes of Cyclin Y. Western blotting was employed to measure protein expression.Results: Cyclin Y was overexpressed in lung cancer, correlating with poor prognosis. Cyclin Y knockdown inhibited cell growth and proliferation, increased DNA damage, inhibited DNA damage repair and increased radiosensitivity in vitro and in vivo. RNA-seq analysis was used to reveal RRM2 as a downstream target gene of Cyclin Y. Cyclin Y depletion down-regulated the protein and mRNA levels of RRM2, leading to reduced STAT3 phosphorylation. Rescue experiments demonstrated that the effect of Cyclin Y on lung cancer was mediated partially by RRM2.Conclusions: We revealed for the first time that targeting Cyclin Y inhibits tumorigenesis and promotes radiosensitivity in lung cancer partially through the RRM2-STAT3 signaling pathway.

2024-10-01 | GSE246182 | GEO

Cyclin K interacts with β-catenin to induce Cyclin D1 expression and facilitate tumorigenesis and radioresistance in lung cancer

Project description:Rationale: Radioresistance remains the major cause of local relapse and distant metastasis in lung cancer. However, the underlying molecular mechanisms remain poorly defined. This study aimed to investigate the role and regulatory mechanism of Cyclin K in lung cancer radioresistance. Methods: Expression levels of Cyclin K were measured by immunohistochemistry in human lung cancer tissues and adjacent normal lung tissues. Cell growth and proliferation, neutral comet and foci formation assays, G2/M checkpoint and a xenograft mouse model were used for functional analyses. Gene expression was examined by RNA sequencing and quantitative real-time PCR. Protein-protein interaction was assessed by immunoprecipitation and GST pull-down assays. Results: We report that Cyclin K is frequently overexpressed and correlates with poor prognosis in lung cancer patients. Functionally, we demonstrate that Cyclin K depletion results in reduced proliferation, defective G2/M checkpoint and enhanced radiosensitivity in lung cancer. Mechanistically, we reveal that Cyclin K interacts with and promotes the stabilization of β-catenin, thereby upregulating the expression of Cyclin D1. More importantly, we show that Cyclin D1 is the major effector that mediates the biological functions of Cyclin K in lung cancer. Conclusions: These findings suggest that Cyclin K positively modulates the β-catenin/Cyclin D1 axis to promote tumorigenesis and radioresistance in lung cancer, indicating that Cyclin K may represent a novel attractive biomarker for lung cancer radiotherapy.

2020-01-07 | GSE143147 | GEO